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ABSTRACT
Motivation: Methods for computational drug target identification
utilize information from diverse information sources to predict or
prioritize drug targets for known drugs. One set of resources that
has been relatively neglected for drug repurposing are animal model
phenotypes.
Results: We investigate the use of mouse model phenotypes for
drug target identification. To achieve this goal, we first integrate
mouse model phenotypes and drug effects, and then systematically
compare the phenotypic similarity between mouse models and drug
effect profiles. We find a high similarity between phenotypes resulting
from loss-of-function mutations and drug effects resulting from the
inhibition of a protein through a drug action, and demonstrate how
this approach can be used to suggest candidate drug targets.
Availability and implementation: Analysis code and supplementary
data files are available on the project website at https://
drugeffects.googlecode.com.
Contact: roh25@aber.ac.uk
INTRODUCTION
A major challenge currently faced by pharmacological research is
the high rate of attrition in the development of new compounds,
the increased cost of drug development, and increased regulatory
concern about drug safety and efficacy (Sleigh and Barton, 2010).
As a result, pharmacological research is beginning to focus
on repurposing existing drugs for new indications, and several
large national and international research initiatives have begun to
systematically address drug repurposing on a broad scale (Allison,
2012).
Strategies for drug repurposing can be divided into two
main types: identification of new targets for known drugs and
identification of new indications for a known mechanism of
action (Sleigh and Barton, 2010). Approaches to drug-repurposing
include database-driven bioinformatics approaches, in vivo and
∗to whom correspondence should be addressed
ex vivo studies and high-throughput screening methods (Sleigh
and Barton, 2010). Examples of computational approaches to
drug repurposing include side-effect based approaches, in which
similarity between drug effects is used to suggest drug targets and
drug indications (Campillos et al., 2008), data mining of clinical
records (Tatonetti et al., 2012), and approaches based on analysis
of GWAS data (Sanseau et al., 2012). Computational approaches to
drug repurposing have the highest chance of succeeding if multiple
independent data sources and analysis approaches are combined
so that data from several independent domains and studies can
be utilized to identify strong evidence for novel drug indications.
Based on integrating multiple complementary datasets, integrative
computational approaches can use multiple measures to prioritize
candidate targets and drugs (Gottlieb et al., 2011; Thorn et al., 2010;
Chen et al., 2012b).
One set of resources that has been relatively neglected for
drug repurposing is animal model phenotypes (Hurle et al.,
2013; Hoehndorf et al., 2012). The use of non-human species
to investigate physiology and patho-biology, and the creation
of animal models of human diseases amenable to experimental
investigation, has become a successful paradigm in the biomedical
sciences (Rosenthal and Brown, 2007). The development of high-
throughput phenotyping has further increased the available amount
of phenotype data resulting from targeted mutations in animal
models, and pan-genomic projects such as the International Mouse
Phenotyping Consortium (IMPC) (Brown and Moore, 2012) aim to
delete every protein-coding gene in an organism and identify the
phenotypes resulting from these mutations. It has now become a
challenge to systematically analyze the resulting data and utilize
them to provide insights into human health and novel intervention
strategies.
In the past, several studies have used animal model data to
suggest candidate genes for genetically based diseases (Chen et al.,
2012a; Hoehndorf et al., 2011b) and one study also suggests that
mouse model phenotypes can be used to provide insights into drug
actions and drug effects in humans despite experimental differences
between the two species (Kuhn et al., 2013). Here, we use a
phenome-wide approach to systematically compare drug effects
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with mutant mouse phenotypes (see Figure 1). We provide strong
supporting evidence for the hypothesis that the similarity between
drug effects and mouse phenotypes that result from loss of protein
function indicates a similarity in the mechanism of action, i.e.,
an inhibition of the protein through the drug. We evaluate our
results with experimentally validated lists of known drug targets
and demonstrate on a genomic scale that a similarity between
drug effects and mutant mouse phenotypes can reveal drug targets.
Our approach opens the possibility for a systematic analysis of
animal model phenotypes for candidate drug targets, and has a
significant impact for integrative computational approaches to drug
repurposing.
Fig. 1. The figure illustrates our basic workflow and the connections
between the different datasets we exploit. We aim to infer inhibition actions
between drugs and their targets based on the similarity between drug
effect profiles and mouse model phenotypes resulting from single gene
knockouts. We test the hypothesis whether the phenotypic effects of a
perturbation of a gene/protein through a drug action bears some similarity to
the phenotypic effects of a targeted mutation of that gene/protein observed
in a model organism. Since drugs often perturb multiple genes/proteins,
we systematically compute how well a drug effect profile covers observed
phenotypes in a mouse model using a non-symmetrical measure of semantic
similarity.
MATERIAL AND METHODS
Mouse model phenotypes
We use the Mammalian Phenotype ontology (MP) (Smith et al., 2004)
and the Human Phenotype Ontology (HPO) (Robinson et al., 2008),
both downloaded on 14 February 2013 from the OBO Foundry website
(http://obofoundry.org). We obtain the Entity-Quality definitions
attached to MP and HPO from https://phenotype-ontologies.
googlecode.com (downloaded on 14 February 2013).
We downloaded mouse phenotype data from the Mouse Genome
Informatics (MGI) database (Blake et al., 2011) on 14 February 2013. We
only obtained mouse model phenotypes associated with models resulting
from loss-of-function mutations in single genes.
Drug effect profiles and drug targets
Drug effect profiles were obtained from SIDER 2 (released on 16 March
2012) (Kuhn et al., 2010). For each drug, we identify the STITCH identifier
associated with the drug. We ignore all drugs for which no STITCH identifier
has been identified in the SIDER dataset. STITCH identifiers are based on
the STITCH database, version 3.1 (Kuhn et al., 2012).
Integrating drug effects and phenotypes
We used a combination of lexical mapping, manual curation and exploitation
of cross-references to map the UMLS terms used to characterize SIDER’s
drug profiles to the Human and Mammalian Phenotype Ontologies. Using
exact lexical matching of UMLS terms to term names and synonyms in
ontologies, we mapped 597 terms from SIDER to the Human Phenotype
Ontology (HPO) (Robinson et al., 2008) and 262 terms from SIDER to the
Mammalian Phenotype Ontology (MP) (Smith et al., 2004). HPO already
contains cross-references to terms from the Unified Medical Language
System (UMLS) (Bodenreider, 2004), 3,858 of which can be found in
SIDER’s drug effect profiles. We sorted the remaining SIDER terms for
which we could not obtain a mapping to HPO or MP based on the frequency
of their occurrence in SIDER drug effect profiles, and manually mapped
953 of the most frequently occurring terms to HPO and 240 of the most
frequently occurring terms to MP. The mappings are available on the project
website.
Cross-species integration of phenotypes
While we have annotated SIDER with both MP and HPO terms, mouse
phenotypes are represented exclusively using MP. To make HPO and
MP phenotype terms comparable, we utilize the PhenomeNET system of
integrating phenotypes across species (Hoehndorf et al., 2011b, 2013).
PhenomeNET enables the direct comparison of phenotypes across multiple
species (Hoehndorf et al., 2011b, 2013), including mouse model phenotypes
(describing using the MP) and human drug effects (described using the
UMLS and mapped to HPO using our approach).
PhenomeNET uses an ontology-based integration framework that
integrates phenotypes in different species based on species-independent
ontologies and the PATO framework (Gkoutos et al., 2005). In particular,
PhenomeNET uses the large number of Entity-Quality-based definitions
that have been created for species-specific phenotype ontology (Mungall
et al., 2010) and integrates them with species-independent ontologies.
Entity-Quality definitions of phenotypes decompose phenotype terms in
an affected entity and a quality that characterizes how the entity is
affected. For example, the phenotype term Proximal fibular overgrowth
(HP:0007126) is decomposed into the entity Proximal epiphysis of
fibula (FMA:33729) and the quality Hypertrophic (PATO:0000584).
Similarly, the mouse phenotype term Abnormal fibula morphology
(MP:0002187) is decomposed into the entity Fibula (MA:0001360) and
the quality Morphology (PATO:0000051) with the qualifier Abnormal
(PATO:0000460).
Phenotypes in which biological processes, functions or cellular
components are affected can then be integrated across species based on the
Gene Ontology (GO) (Ashburner et al., 2000), and phenotypes in which
anatomical structures are affected are integrated based on homologous
anatomical structures represented in the UBERON ontology (Mungall et al.,
2012). Using automated reasoning (Kazakov et al., 2011), it then becomes
possible to systematically identify equivalent, more specific and more
general phenotypes across multiple species. For example, based on axioms
in the combined ontology, we can infer that Proximal fibular overgrowth is
a more specific phenotype term than Abnormal fibula morphology using the
information that
• Fibula (MA:0001360) is homologous to Fibula (FMA:24479) (from
the UBERON ontology),
• Proximal epiphysis of fibula (FMA:33729) is a part-of Fibula
(FMA:24479) (from the FMA), and
• Hypertrophic (PATO:0000584) is a more specific quality than
Morphology (abnormal) (PATO:0000460).
Additional details for integrating phenotype ontologies across species using
the Web Ontology Language (OWL) (Grau et al., 2008) are discussed in
prior work (Hoehndorf et al., 2011a, 2010, 2011b).
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Semantic similarity
Traditional semantic similarity measures are symmetrical, i.e., the similarity
between X and Y is the same as the similarity between Y and X . Since
drugs may bind to multiple targets to elicit their effects (Kuhn et al., 2013),
we designed a novel, non-symmetrical similarity measure based on the well-
known SimGIC measure (Pesquita et al., 2009). SimGIC is a group-based
measure of semantic similarity, i.e., it compares two sets of annotations
directly, and is based on the Jaccard index weighted by the information
content of ontology terms (Pesquita et al., 2009).
We first select all phenotypes observed for single gene deletions in mice.
For each gene G for which phenotype data is present in the MGI database,
we then generate the union of the phenotypes observed in all models in
which G has been deleted. The resulting phenotypes for a gene G are
all phenotypes observed in mouse models in which G (and only G) has
been deleted and provides a global view on the phenotypes associated with
deletions of G.
We then add the super-classes of the phenotype annotations of each mouse
model and drug to their set of annotations. In particular, if the HPO or MP
phenotype P is a phenotype annotation associated with gene or drugX , and
the super-classes of X in MP are the classes Sup(X), we add Sup(X) as
annotations toX . To compute super-classes, we use the combined ontology
of MP and HPO that forms part of PhenomeNET and enables cross-species
comparisons of phenotypes (i.e., a class in MP may be a super-class of a
class in HPO and vice versa) (Hoehndorf et al., 2011b). We make the MP-
based representation of drug effects in SIDER based on which we compute
the similarity available on the project website.
We then define the information content IC(t) of an MP phenotype term
t based on the probability P (X = t) that a drug or mutant mouse model is
characterized with t:
IC(t) = − log(P (X = t)) (1)
The probabilityP (X = t) is empirically derived within the corpus of mouse
models and drug profiles. We use only the structure of the MP to compute
semantic similarity based on prior work that has shown that MP-based
similarity measures outperform measures that use HPO or the combination
of HPO and MP for analyzing mouse phenotype data (Oellrich et al., 2012).
Given a drug effect profile D and a mutant mouse model M , where D
is characterized by the ontology classes Cl(D) = D1, ..., Dn and M
is characterized by the classes Cl(M) = M1, ...,Mm, we define the
similarity betweenD andM as:
sim(D,M) =
∑
x∈Cl(D)∩Cl(M)
IC(x)
∑
y∈Cl(D)
IC(y)
(2)
As a result, we obtain a similarity matrix between drug effect profiles
and mouse model phenotypes (resulting from deletions of one gene). The
similarity measure used is non-symmetrical and determines the amount of
information about a drug effect profile D that is covered by a set of mouse
model phenotypesM .
Evaluation datasets
Our approach is based on identifying a similarity between drug effect profiles
and mouse model phenotypes. The STITCH database provides us with a
set of drug-protein interactions in the mouse. We filter these interactions
for those in which the mode of action is “inhibition” (in the STITCH file
actions.v3.1.tsv) and use this dataset directly as evaluation dataset
“STITCH (mouse)”.
As we primarily aim to predict drug targets in human, we use the
human-mouse orthology provided by the Mouse Genome Informatics (MGI)
database (Blake et al., 2011) to obtain the mouse ortholog for each human
gene that is a target of a STITCH compound, and use the mouse ortholog
of the human drug target as a positive hit for the STITCH compound. We
use the human drug-protein interactions provided by STITCH in which the
mode of action is “inhibition” as evaluation dataset “STITCH (human)”, and
the human drug targets provided by DrugBank in which the mode of action
is “inhibition” as evaluation dataset “DrugBank”.
The STITCH database accumulates data from multiple sources and
contains a confidence value for each interaction. The confidence ranges
between 0 and 1, with an implicit cutoff value of 0.15. To evaluate the
results of our analysis under different degrees of confidence, we generated
evaluation datasets for STITCH in which we require a confidence of at least
0.5, and another dataset in which we require a confidence of at least 0.7. The
evaluation datasets we used are available on the project website.
ROC analysis and approximation of confidence intervals
To compute true and false positive rate, we iterate through the ranks of the
generated similarity matrix (between drugs and mouse models) and compute,
for each rank, the proportion of known drug targets in each of our evaluation
datasets identified up to this rank (true positive rate) as well as the proportion
of targets not in the evaluation dataset included up to this rank (false positive
rate). We then use an analysis of the receiver operating characteristic (ROC)
curve to evaluate and quantify the results. A ROC curve is a plot of the true
positive rate as a function of the false positive rate and can be used to evaluate
the performance of a classifier (Fawcett, 2006).
Confidence intervals for the area under the ROC curve (ROCAUC) are
computed under the assumption of a normal distribution of ROCAUC values
and using an estimate of the maximum variance of the ROCAUC as σ2max =
AUC(1−AUC)
min{m,n}
, with m and n being the number of positive and negative
instances in the evaluation dataset (Birnbaum and Klose, 1957). We then use
AUC±2σ as an estimate of the 95% confidence interval (Cortes and Mohri,
2005).
RESULTS
Mouse model phenotypes provide information about
drug targets
The hypothesis we test is whether a similarity between drug D’s
effects and phenotypes resulting from knock-out/knock-down of a
single gene (product) in an animal model can be used to indicate that
D inhibits the gene (product), or its human ortholog, and whether
phenotype similarity between mouse models and drug effects can
be used to provide insights relevant for discovery of targets for
known drugs. To test these hypotheses, we first made drug effects
and mouse phenotypes comparable by mapping the drug effects
described in the SIDER database (Kuhn et al., 2010) to human and
mouse phenotype terms, and then integrating human and mouse
phenotypes across species (see Materials and Methods).
Once mouse model phenotypes and human drug effects are made
directly comparable, we use a measure of semantic similarity
(Pesquita et al., 2008) to compare drug effect profiles with
mutant mouse phenotypes. We systematically compare the sets
of phenotypes that have been observed in mice with single
gene deletions to drug effect profiles obtained from the SIDER
database, and use their similarity to prioritize candidate drug-protein
interactions. To account for drugs’ binding to multiple targets, we
developed a novel similarity measure between drug effect profiles
and mouse model phenotypes that determines how much of the
information in the drug effect profile can be explained through a set
of mouse model phenotypes (Materials and Methods). A schematic
overview of the approach is shown in Figure 1.
We evaluate the results using three datasets: the human drug
targets available in DrugBank (Knox et al., 2011), the human
drug targets available in the STITCH database (Kuhn et al.,
2012), and the mouse drug targets available in the STITCH
3
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database. DrugBank contains experimentally validated drug targets
and includes information on the mode of action. Similarly, STITCH
accumulates information about human and animal drug targets from
multiple sources and includes the mode of action, if known. For our
evaluation, we select only drug targets for which the mechanism
of action is inhibition since we aim to test whether these provide
a similar phenotypic response as a knock-out/knock-down of the
target.
For each drug, we identify the similarity between its
pharmacological effects and the phenotypes observed in mouse
models with a single gene deletion and rank the mouse models,
for each drug, based on their similarity to the drug effect profile.
We then evaluate the resulting ranks using positive instances of
drug–target interactions, and Figure 2 shows the resulting ROC
curves for the three main datasets we used. The ROCAUC values
are 0.739 ± 0.011 for mouse targets (STITCH), 0.709 ± 0.009
for human targets (STITCH) and 0.723 ± 0.040 for human targets
(DrugBank). We further restricted the STITCH evaluation datasets
for human and mouse to high-confidence drug-protein interactions.
With a confidence cutoff of 0.5, the resulting AUCs are 0.760 ±
0.010 for human targets and 0.797 ± 0.016 for mouse targets, and
with a cutoff of 0.7 the AUCs are 0.762 ± 0.011 for human and
0.820± 0.024 for mouse targets.
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Fig. 2. The ROC curves for our three evaluation datasets. DrugBank consists
of experimentally verified and manually annotated drug-target interactions.
STITCH integrates drug-target relations from multiple databases (including
DrugBank), applies text mining and network-based inference approaches to
infer drug-target relations. We used human-mouse orthology available from
the MGI database to map human proteins in the DrugBank and STITCH
(human) dataset to mouse proteins.
Targets in different protein families can be predicted
with different accuracy
We further investigated whether our approach is more successful
for particular protein families or particular drug categories. For
this purpose, we performed our analysis for each of the top-
level InterPro (Mulder et al., 2005) protein families. To maintain
statistical significance, we restrict our analysis to protein families
in which we could identify more than 5 positive instances from our
evaluation datasets, resulting in only six protein families for which
we perform the analysis using the two STITCH-based evaluation
datasets. The resulting ROCAUCs are shown in Table 1 and Figure
3. The ROC AUCs range from 0.222± 0.339 (for NAD(P)-binding
domain proteins) to 0.927 ± 0.083 (for Steroid hormone receptor
proteins).
We further performed our analysis for different categories of
drugs to test whether our approach is more successful for some
classes of drugs than others. For this purpose, we divide drugs into
different groups based on their top-level category in the Anatomical
Therapeutic Classification (ATC) (Miller and Britt, 1995) and
evaluated each group individually (Supplementary Table 1 and
Supplementary Figure 1).
Example prediction: diclofenac
One example of our method’s predictive power is the identification
of similar effects between PPARg (MGI:97747) and the
drug diclofenac (STITCH:000003032). Diclofenac is a non-
steroidal anti-inflammatory drug (NSAID) acting primarily as a
cyclooxygenase (preferential COX-2) inhibitor and is used to treat
a variety of acute and chronic pain and inflammatory conditions. In
recent years, additional modes of action have been discerned which
in many cases have no known mechanism. For example, diclofenac
has been shown to inhibit the thromboxane-prostanoid receptor,
affect arachidonic acid release and uptake, inhibit lipoxygenase
enzymes, and activate the nitric oxide-cGMP antinociceptive
pathway (Gan, 2010). Using our approach, we have compared the
drug effect profile of diclofenac across the gathered phenotypic
data and find a high similarity to phenotypes produced by Pparg
knockout mice. Using our method, 49% of the information
content associated with diclofenac’s pharmacological effects can
be explained through the hypothesis that it inhibits Pparg or its
pathway in mice. Pparg is a member of the steroid hormone receptor
superfamily, which includes the estrogen and thyroid hormone
receptors, and regulates the expression of genes involved in
inflammation and lipid homeostasis. Despite its anti-inflammatory
indications, diclofenac is associated with the induction of dermatitis,
alopecia, erythema, exfoliative dermatitis, and eczema, along with
hepatitis and other widespread systemic phenotypes. Several of
these phenotypes can also be identified in mice (Harries and Paus,
2009; Wahli, 2002). In 2002, diclofenac was implicated as a partial
agonist of Pparg, acting as a competitive antagonist and inhibiting
PPARg signaling at normal therapeutic doses (Adamson et al.,
2002), suggesting that a significant proportion of diclofenac’s side
effects might be explained through this mechanism. The apparent
pro-inflammatory effects of diclofenac seen, for example, in the
skin are therefore likely to be a consequence of the effects on the
Pparg pathway in non-immune cells, and recent research suggests
that it is the effect on the inhibition of PPARg in the pilosebaceceous
4
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number of drug effects in SIDER that cover most observed mouse
model phenotypes. For example, the genes Gt(ROSA)26Sor (gene
trap ROSA 26, Philippe Soriano) (MGI:104735), phosphatase
and tensin homolog (Pten, MGI:109583), apolipoprotein E
(Apoe MGI:88057), or leptin receptor (Lepr, MGI:104993)
are associated with a large number of phenotypes covering most
branches of the MP and are ranked among the first mouse genes
for most compounds in SIDER. Similarly, drugs such as pregabalin
(STITCH:005486971) or fluoxetine (STITCH:000003386)
are associated with a large number of drug effects in SIDER and
are ranked in the first places for most mouse genes. These artifacts
of our similarity measure result in a decreased performance when
analyzing the complete dataset and not applying any additional
filtering. In particular, the highest-ranking associations resulting
from our approach are, in most cases, false positives due to the
artifacts generated by the similarity measure, and these artifacts
result in a worse-than-random performance in the ROC analysis for
low false-positive-rates.
However, our measure also has significant advantages over
symmetric similarity measures. We have evaluated commonly
applied group-wise similarity measures (Pesquita et al., 2009) for
our data set, in particular the Jaccard index and the SimGIC
measure. We found the results to be significantly worse than when
applying our measure (ROCAUC values are 0.579 for STITCH
(mouse) and 0.566 for STITCH (human); raw data available on
project website). The major difference between our similarity
measure and group-wise measures such as SimGIC is the symmetry
property. In particular, symmetric group-wise similarity measures
score mismatches negatively. In our application, we compare large
sets of phenotypes observed as drug effects with the phenotypes
observed for single gene deletions in mice. If different drug
effects are caused by different proteins with which the drug
interacts, we expect only a small portion of the effects to be
covered by the phenotypes of a single gene knockout. Negatively
scoring all non-matching drug effects introduces noise that increases
with the number of drug effects and leads to the significantly
lower performance in the ROC analysis. Furthermore, symmetric
similarity measures are applicable when comparing essentially
similar entities. As most chemical compounds in SIDER interact
with many proteins, we compare sets of phenotypes resulting
from perturbations of many proteins (drug effects) to sets of
phenotypes resulting from perturbations of single proteins, and in
the case of comparing non-similar entities such as drug effects and
knockout phenotypes, our non-symmetric similarity measure seems
to perform better than symmetric group-wise measures.
Applications in drug repurposing and target discovery
The results of our analyses support the hypothesis that the
systematic analysis of similarity between drug effects and mouse
model phenotypes can be used to provide insights into drug
actions. While experimental validation is required to determine
the suitability of such an approach for the discovery of novel
drug targets, our computational evaluation shows that, at least
for some protein families, our approach is highly successful (up
to 0.927 ± 0.083 ROCAUC) and therefore may prove promising
for integrative approaches towards computational drug repurposing.
Our approach is less successful for some protein classes, such as
voltage-dependent potassium channel or NAD(P)-binding domain
proteins. However, our evaluation datasets contain relatively few
positive instances for such classes, indicated by the confidence
intervals in Figure 3.
Our work further confirms the hypothesis of Kuhn et al. (Kuhn
et al., 2013), who mapped 116 mouse phenotype terms to drug
effect terms and evaluated 398 knockout mice in an effort to
identify proteins that underlie particular drug effects. Kuhn et al.
formulated the hypothesis “that a deletion of a protein in mice
is likely to elicit the same phenotype as inhibiting the respective
ortholog in humans despite species and methodology differences”.
However, while Kuhn et al. used this approach in the context of
investigating the role of proteins in eliciting drug side effects, our
approach provides evidence for the potential of applying mouse
models for revealing novel drug-target interactions. Additionally,
we systematically evaluated the whole mouse phenome and provide
a ranked list of candidate drug targets spanning all drugs in the
SIDER database and every protein for which phenotypes have been
created in the mouse.
Integrative approaches to drug repurposing and drug target
identification take advantage of multiple independent data sources
to provide high-confidence predictions of novel indications or
novel targets for known drugs (Dudley et al., 2011; Hurle et al.,
2013). Our approach will be most useful as a component in
integrative approaches to drug repurposing or target identification.
In both tasks, the use of animal models is currently largely under-
represented despite its potential to provide novel, independent
information that strengthens already successful systems (Hurle
et al., 2013).
Furthermore, our method is not based on the “guilt-by-
association” principle (Gillis and Pavlidis, 2012) as is applied
in side-effect based approaches to drug repurposing (Campillos
et al., 2008) or other similarity-based approaches (Gottlieb et al.,
2011), nor is our method based on data mining clinical records
(Tatonetti et al., 2012); instead, it utilizes experimental data
from genetically modified animal organisms. Our evaluation
demonstrates that our method may even be used independently for
some categories of targets, particularly steroid hormone receptors,
although additional experimental validation is required to further
support this hypothesis.
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